2022
Animal models of the immunology and pathogenesis of human babesiosis
Kumar A, Kabra A, Igarashi I, Krause P. Animal models of the immunology and pathogenesis of human babesiosis. Trends In Parasitology 2022, 39: 38-52. PMID: 36470781, DOI: 10.1016/j.pt.2022.11.003.Peer-Reviewed Original ResearchConceptsAnimal modelsHuman babesiosisBabesia infectionImmunological mechanismsModerate diseaseOrgan dysfunctionPathologic responseDisease complicationsAsymptomatic infectionSevere diseaseAnimal studiesInfectionPathological processesDiseaseBabesiosisBabesia speciesAnimalsDomestic animalsComplicationsDysfunctionPathogenesisImmunology
2021
Tick hypersensitivity and human tick‐borne diseases
Ng YQ, Gupte TP, Krause PJ. Tick hypersensitivity and human tick‐borne diseases. Parasite Immunology 2021, 43: e12819. PMID: 33428244, DOI: 10.1111/pim.12819.Peer-Reviewed Original ResearchConceptsHypersensitivity reactionsImmune responseBlood mealTick-borne diseasesGeneralized hypersensitivity reactionHuman tick-borne diseasesHost immune responseLocal hypersensitivity reactionsLaboratory animal modelsItch responseCausative pathogenTick exposureSuch vaccinesTick salivary proteinsAnimal modelsAnti-tick vaccinesMost vector-borne diseasesTick salivaHuman investigationsDiseaseTick attachmentFuture preventionBlood coagulationHypersensitivity studiesVaccineClinical Practice Guidelines by the Infectious Diseases Society of America (IDSA): 2020 Guideline on Diagnosis and Management of Babesiosis
Krause PJ, Auwaerter PG, Bannuru RR, Branda JA, Falck-Ytter YT, Lantos PM, Lavergne V, Meissner HC, Osani MC, Rips JG, Sood SK, Vannier E, Vaysbrot EE, Wormser GP. Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA): 2020 Guideline on Diagnosis and Management of Babesiosis. Clinical Infectious Diseases 2021, 72: 185-189. PMID: 33501959, DOI: 10.1093/cid/ciab050.Peer-Reviewed Original ResearchConceptsInfectious Diseases SocietyDiseases SocietyInfectious disease specialistsClinical practice guidelinesPrimary care physiciansTransfusion medicine specialistsEvidence-based guidanceHuman granulocytic anaplasmosisRheumatology guidelinesDisease guidelinesCare physiciansDisease specialistsEmergency physiciansPractice guidelinesAmerican CollegeMedicine specialistsAmerican AcademyDisease controlLyme diseaseGranulocytic anaplasmosisDiagnosisPhysiciansBabesiosisGuidelinesTreatment
2020
Borrelia burgdorferi and Borrelia miyamotoi seroprevalence in California blood donors
Brummitt SI, Kjemtrup AM, Harvey DJ, Petersen JM, Sexton C, Replogle A, Packham AE, Bloch EM, Barbour AG, Krause PJ, Green V, Smith WA. Borrelia burgdorferi and Borrelia miyamotoi seroprevalence in California blood donors. PLOS ONE 2020, 15: e0243950. PMID: 33370341, PMCID: PMC7769429, DOI: 10.1371/journal.pone.0243950.Peer-Reviewed Original ResearchConceptsLyme diseaseBlood donorsB. miyamotoiB. burgdorferiEndemic countiesWestern blotBorrelia miyamotoiB. burgdorferi antibodiesAdult blood donorsBorrelia burgdorferiIgG Western blotBlood donor seraRisk of infectionELISA test systemBurgdorferi antibodiesDonor seraC6 ELISAClinical casesEquivocal samplesHuman casesDiseaseAntibodiesI. pacificus ticksMiyamotoiBurgdorferiClinical Practice Guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 Guidelines for the Prevention, Diagnosis and Treatment of Lyme Disease
Lantos PM, Rumbaugh J, Bockenstedt LK, Falck-Ytter YT, Aguero-Rosenfeld ME, Auwaerter PG, Baldwin K, Bannuru RR, Belani KK, Bowie WR, Branda JA, Clifford DB, DiMario FJ, Halperin JJ, Krause PJ, Lavergne V, Liang MH, Meissner HC, Nigrovic LE, Nocton J, Osani MC, Pruitt AA, Rips J, Rosenfeld LE, Savoy ML, Sood SK, Steere AC, Strle F, Sundel R, Tsao J, Vaysbrot EE, Wormser GP, Zemel LS. Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 Guidelines for the Prevention, Diagnosis and Treatment of Lyme Disease. Clinical Infectious Diseases 2020, 72: e1-e48. PMID: 33417672, DOI: 10.1093/cid/ciaa1215.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsInfectious Diseases SocietyClinical practice guidelinesLyme diseaseDiseases SocietyPractice guidelinesAmerican CollegeEvidence-based clinical practice guidelinesAmerican AcademyTick-borne rickettsial infectionInfectious disease specialistsPrimary care physiciansRheumatologic manifestationsCare physiciansErythema migransDisease specialistsMultidisciplinary panelEmergency physiciansFamily physiciansRickettsial infectionTick-borne pathogensDiseaseSeparate guidelinesPhysiciansDiagnosisPreventionClinical Practice Guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 Guidelines for the Prevention, Diagnosis and Treatment of Lyme Disease
Lantos PM, Rumbaugh J, Bockenstedt LK, Falck-Ytter YT, Aguero-Rosenfeld ME, Auwaerter PG, Baldwin K, Bannuru RR, Belani KK, Bowie WR, Branda JA, Clifford DB, DiMario FJ, Halperin JJ, Krause PJ, Lavergne V, Liang MH, Meissner HC, Nigrovic LE, Nocton JJJ, Osani MC, Pruitt AA, Rips J, Rosenfeld LE, Savoy ML, Sood SK, Steere AC, Strle F, Sundel R, Tsao J, Vaysbrot EE, Wormser GP, Zemel LS. Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 Guidelines for the Prevention, Diagnosis and Treatment of Lyme Disease. Clinical Infectious Diseases 2020, 72: 1-8. PMID: 33483734, DOI: 10.1093/cid/ciab049.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsInfectious Diseases SocietyClinical practice guidelinesLyme diseaseDiseases SocietyPractice guidelinesAmerican CollegeEvidence-based clinical practice guidelinesAmerican AcademyTick-borne rickettsial infectionInfectious disease specialistsPrimary care physiciansRheumatologic manifestationsCare physiciansErythema migransDisease specialistsMultidisciplinary panelEmergency physiciansFamily physiciansRickettsial infectionTick-borne pathogensDiseaseSeparate guidelinesPhysiciansDiagnosisPreventionClinical Practice Guidelines by the Infectious Diseases Society of America (IDSA): 2020 Guideline on Diagnosis and Management of Babesiosis
Krause PJ, Auwaerter PG, Bannuru RR, Branda JA, Falck-Ytter YT, Lantos PM, Lavergne V, Meissner HC, Osani MC, Rips JG, Sood SK, Vannier E, Vaysbrot EE, Wormser GP. Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA): 2020 Guideline on Diagnosis and Management of Babesiosis. Clinical Infectious Diseases 2020, 72: e49-e64. PMID: 33252652, DOI: 10.1093/cid/ciaa1216.Peer-Reviewed Original ResearchConceptsInfectious Diseases SocietyDiseases SocietyInfectious disease specialistsClinical practice guidelinesPrimary care physiciansTransfusion medicine specialistsEvidence-based guidanceHuman granulocytic anaplasmosisRheumatology guidelinesDisease guidelinesCare physiciansDisease specialistsEmergency physiciansPractice guidelinesAmerican CollegeMedicine specialistsAmerican AcademyDisease controlLyme diseaseGranulocytic anaplasmosisDiagnosisPhysiciansBabesiosisGuidelinesTreatmentAntigen Discovery, Bioinformatics and Biological Characterization of Novel Immunodominant Babesia microti Antigens
Verma N, Puri A, Essuman E, Skelton R, Anantharaman V, Zheng H, White S, Gunalan K, Takeda K, Bajpai S, Lepore TJ, Krause PJ, Aravind L, Kumar S. Antigen Discovery, Bioinformatics and Biological Characterization of Novel Immunodominant Babesia microti Antigens. Scientific Reports 2020, 10: 9598. PMID: 32533024, PMCID: PMC7293334, DOI: 10.1038/s41598-020-66273-6.Peer-Reviewed Original ResearchConceptsPotential biological functionsBiological functionsCellular localization studiesB. microtiEvolutionary relationshipsDomain architectureBioinformatics analysisRecombinant proteinsExtracellular domainLocalization studiesPrimary causative agentUnrelated groupsE. coliBiological characterizationNovel assayIntraerythrocytic parasitesBabesia microtiDistinct classesProteinCausative agentAntigen discoveryGlobal public health impactB. microti antibodiesB. microti antigenTransfusion of bloodManagement strategies for human babesiosis
Smith RP, Hunfeld KP, Krause PJ. Management strategies for human babesiosis. Expert Review Of Anti-infective Therapy 2020, 18: 625-636. PMID: 32268823, DOI: 10.1080/14787210.2020.1752193.Peer-Reviewed Original ResearchClofazimine, a Promising Drug for the Treatment of Babesia microti Infection in Severely Immunocompromised Hosts
Tuvshintulga B, Vannier E, Tayebwa DS, Gantuya S, Sivakumar T, Guswanto A, Krause PJ, Yokoyama N, Igarashi I. Clofazimine, a Promising Drug for the Treatment of Babesia microti Infection in Severely Immunocompromised Hosts. The Journal Of Infectious Diseases 2020, 222: 1027-1036. PMID: 32310272, DOI: 10.1093/infdis/jiaa195.Peer-Reviewed Original ResearchConceptsB. microti parasitesMicroti infectionHigh-grade parasitemiaDrug-resistant tuberculosisB. microtiBabesia microti infectionAdditional preclinical studiesB. microti infectionImmunocompromised hostB. microti DNAPolymerase chain reactionPreclinical studiesIncidence of babesiosisPromising drugRadical cureMinimal doseClofazimineDay 10Blood smearsBabesia microtiNovel drugsParasitemiaChain reactionMicroscopic examinationAntimicrobial agents
2019
Seroprevalence of <em>Borrelia burgdorferi</em>, <em>B. miyamotoi</em>, and Powassan Virus in Residents Bitten by <em>Ixodes</em> Ticks, Maine, USA - Volume 25, Number 4—April 2019 - Emerging Infectious Diseases journal - CDC
Smith RP, Elias SP, Cavanaugh CE, Lubelczyk CB, Lacombe EH, Brancato J, Doyle H, Rand PW, Ebel GD, Krause PJ. Seroprevalence of Borrelia burgdorferi, B. miyamotoi, and Powassan Virus in Residents Bitten by Ixodes Ticks, Maine, USA - Volume 25, Number 4—April 2019 - Emerging Infectious Diseases journal - CDC. Emerging Infectious Diseases 2019, 25: 804-807. PMID: 30882312, PMCID: PMC6433028, DOI: 10.3201/eid2504.180202.Peer-Reviewed Original Research
2018
BmGPAC, an Antigen Capture Assay for Detection of Active Babesia microti Infection
Thekkiniath J, Mootien S, Lawres L, Perrin BA, Gewirtz M, Krause PJ, Williams S, Doggett J, Ledizet M, Mamoun C. BmGPAC, an Antigen Capture Assay for Detection of Active Babesia microti Infection. Journal Of Clinical Microbiology 2018, 56: 10.1128/jcm.00067-18. PMID: 30093394, PMCID: PMC6156295, DOI: 10.1128/jcm.00067-18.Peer-Reviewed Original ResearchConceptsHuman babesiosisBabesia microti infectionCapture enzyme-linked immunosorbent assayAntigen capture enzyme-linked immunosorbent assayAntigen capture assayEnzyme-linked immunosorbent assayZoonotic infectious diseaseAcute infectionBlood transfusionAsymptomatic infectionMicroti infectionReal-time PCRBlood supplyAnimal reservoir hostsDonor bloodEpidemiological surveyHuman patientsImmune systemSerological assaysImmunodominant antigensInfectionInfectious diseasesIntraerythrocytic protozoan parasitePatientsImmunosorbent assayResponse to “Transfusion‐transmitted and community‐acquired babesiosis in New York, 2004 to 2015: a response to why and what to do”
Fish D, Krause PJ. Response to “Transfusion‐transmitted and community‐acquired babesiosis in New York, 2004 to 2015: a response to why and what to do”. Transfusion 2018, 58: 1818-1819. PMID: 30133825, DOI: 10.1111/trf.14761.Peer-Reviewed Original ResearchConceptsResponseCommunity‐acquired and transfusion‐transmitted babesiosis are increasing: why and what to do?
Kumar S, Fish D, Krause PJ. Community‐acquired and transfusion‐transmitted babesiosis are increasing: why and what to do? Transfusion 2018, 58: 617-619. PMID: 29528151, DOI: 10.1111/trf.14518.Peer-Reviewed Original Research
2017
Case report of the patient source of the Babesia microti R1 reference strain and implications for travelers
Stahl P, Poinsignon Y, Pouedras P, Ciubotaru V, Berry L, Emu B, Krause PJ, Mamoun C, Cornillot E. Case report of the patient source of the Babesia microti R1 reference strain and implications for travelers. Journal Of Travel Medicine 2017, 25: tax073. PMID: 29394381, PMCID: PMC6927858, DOI: 10.1093/jtm/tax073.Peer-Reviewed Original ResearchConceptsIndirect immunofluorescence antibody testingBabesiosis casesB. microti antibodiesB. microtiTreatment of babesiosisImmunofluorescence antibody testingB. microti infectionNon-endemic areasDiagnosis of babesiosisMicroti antibodiesFebrile illnessImmunocompetent patientsRed blood cellsAntibody testingB. microti DNAPhysical examinationCase reportMedical historyMicroti infectionTick biteClinical informationEndemic areasPatient sourcePatientsBlood smears
2016
Hard Tick Relapsing Fever Caused by Borrelia miyamotoi in a Child
Krause P, Schwab J, Narasimhan S, Brancato J, Xu G, Rich SM. Hard Tick Relapsing Fever Caused by Borrelia miyamotoi in a Child. The Pediatric Infectious Disease Journal 2016, 35: 1352-1354. PMID: 27626914, PMCID: PMC5106309, DOI: 10.1097/inf.0000000000001330.Peer-Reviewed Original Research
2015
Coinfection by Ixodes Tick-Borne Pathogens: Ecological, Epidemiological, and Clinical Consequences
Diuk-Wasser MA, Vannier E, Krause PJ. Coinfection by Ixodes Tick-Borne Pathogens: Ecological, Epidemiological, and Clinical Consequences. Trends In Parasitology 2015, 32: 30-42. PMID: 26613664, PMCID: PMC4713283, DOI: 10.1016/j.pt.2015.09.008.Peer-Reviewed Original ResearchConceptsB. microtiDisease severityGreater disease severityEnzootic cycleCoinfected individualsTick-borne pathogenClinical consequencesTherapeutic strategiesLyme diseaseBabesia microtiHost factorsCoinfectionBorrelia burgdorferiB. burgdorferiIxodes ticksMicrotiReservoir hostsSeverityHuman pathogensBurgdorferiApheresis for babesiosis: Therapeutic parasite reduction or removal of harmful toxins or both?
Saifee NH, Krause PJ, Wu Y. Apheresis for babesiosis: Therapeutic parasite reduction or removal of harmful toxins or both? Journal Of Clinical Apheresis 2015, 31: 454-458. PMID: 26481763, DOI: 10.1002/jca.21429.Peer-Reviewed Original ResearchConceptsExchange transfusionHigh-risk populationLife-threatening illnessApparent therapeutic benefitBlood transfusionModerate diseaseClinical presentationAsymptomatic infectionSevere babesiosisSevere diseaseRisk populationsTherapeutic benefitTransfusionMortality rateIntraerythrocytic protozoan parasiteBabesia infectionDiseaseIxodes ticksProtozoan parasiteBabesiosisInfectionGenus BabesiaMost casesPatientsClindamycinBorrelia miyamotoi infection in nature and in humans
Krause PJ, Fish D, Narasimhan S, Barbour AG. Borrelia miyamotoi infection in nature and in humans. Clinical Microbiology And Infection 2015, 21: 631-639. PMID: 25700888, PMCID: PMC4470780, DOI: 10.1016/j.cmi.2015.02.006.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsB. miyamotoi infectionMiyamotoi infectionClinical manifestationsB. miyamotoiLyme diseaseBorrelia miyamotoi infectionAcute febrile illnessCommon clinical manifestationsBlood smear examinationPublic health importanceHuman granulocytic anaplasmosisFever group spirochetesFebrile illnessAntibiotic therapyDisease groupEtiologic diagnosisSevere diseaseSmear examinationIxodes persulcatus ticksHealth importanceInfectionHuman casesGranulocytic anaplasmosisBorrelia miyamotoiDisease
2014
Babesiosis in China, an emerging threat
Vannier E, Krause PJ. Babesiosis in China, an emerging threat. The Lancet Infectious Diseases 2014, 15: 137-139. PMID: 25539585, DOI: 10.1016/s1473-3099(14)71062-x.Peer-Reviewed Original Research